The profile of lipid metabolites in urine of marmoset wasting syndrome

Abstract

Marmoset wasting syndrome (MWS) is clinically characterized by progressive weight loss. Although morbidity and mortality of MWS are relatively high in captive marmosets, its causes remain unknown. Lipid mediators are bioactive metabolites which are produced from polyunsaturated fatty acids, such as arachidonic acid (AA) and eicosapentaenoic acid. These lipid metabolites regulate a wide range of inflammatory responses and they are excreted into the urine. As urinary lipid profiles reflect systemic inflammatory conditions, we comprehensively measured the levels of 141 types of lipid metabolites in the urines obtained from healthy common marmoset (Callithrix jacchus) (N = 7) or marmosets with MWS (N = 7). We found that 41 types of metabolites were detected in all urine samples of both groups. Among them, AA-derived metabolites accounted for 63% (26/41 types) of all detected metabolites. Notably, the levels of AA-derived prostaglandin (PG) E 2 , PGF 2α , thromboxane (TX) B 2 and F 2-isoprostanes significantly increased in the urine samples of marmosets with MWS. In this study, we found some urinary lipid metabolites which may be involved in the development of MWS. Although the cause of MWS remains unclear, our findings may provide some insight into understanding the mechanisms of development of MWS.

8‐ iso ‐prostaglandin E 2 induces nasal obstruction via thromboxane receptor in murine model of allergic rhinitis

“…Data were analyzed by LabSolutions LCMS version 5.80 (Shimadzu). Qualitative analysis of eicosanoids was performed by using LC/MS/MS Method Package for Lipid Mediators version 2 with LabSolutions software (Shimadzu, Kyoto, Japan) as previously described 9 . The value of each metabolite was calculated as follows; The peak area of each metabolite/the peak area of internal standards.…”

“…Qualitative analysis of eicosanoids was performed by using LC/MS/ MS Method Package for Lipid Mediators version 2 with LabSolutions software (Shimadzu, Kyoto, Japan) as previously described. 9 The value of each metabolite was calculated as follows; The peak area of each metabolite/ the peak area of internal standards. In quantification of 8-iso-PGE 2 and TXB 2 , MS/MS was optimized in the multiple reaction-monitoring in negative ion electrospray mode.…”

The Common Marmoset—Biomedical Research Animal Model Applications and Common Spontaneous Diseases

“…88 Recent reports proposed elevated serum matrix metalloproteinase 9 and urinary lipid metabolites, including prostaglandins, as potential biomarkers. 100,101 For treatment, glucocorticoids such as budesonide are an effective therapeutic option to improve clinical signs in marmosets with chronic lymphocytic enteritis. 89 A recent report demonstrated that tranexamic acid, a plasmin inhibitor, has a therapeutic potential by suppressing certain inflammatory cytokines.…”